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remains unclear. We performed DNMT1 promoter luciferase assay 
and found that wild type p53 could negatively regulate the DNMT1 
promoter, whereas mutant p53 could activate DNMT1 promoter activ-
ity. The physical binding of wild type p53 and mutant p53 to DNMT1 
promoters was identiﬁed by chromatin immunoprecipitation. These 
data suggest that deregulation of DNMTs is associated with the loss of 
transcriptional repression of p53. The p53 mutation results in overex-
pression of DNMT1 and hypermethyaltion of target tumor suppressor 
genes and ultimately leads to tumorigenesis.
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Female-non-smokers with lung adenocarcinomas is becoming promi-
nent among Asian patients with lung cancer. The clinical parameters 
of gender, smoking habits, tumor histology, ethnic origin and EGFR 
mutation status were identiﬁed as predictors of clinical response to 
targeted therapy. The aim of this study was to identify the gene expres-
sion proﬁles of lung adenocarcinomas compared to normal lungs, with 
respect to gender difference, smoking habits and tumor EGFR mutation 
status among Hong Kong Chinese patients with lung adenocarcinomas. 
Total RNA extracted from 49 lung adenocarcinomas and 9 normal lung 
tissues and hybridized onto Affymetrix GeneChip HG-U133 Sets. Data 
were normalized and subjected to repeated iterations of unsupervised 
hierarchical clustering, with independent validation microarray data 
sets, for identiﬁcation of stable sample clustering, followed by super-
vised analysis with Signiﬁcance Analysis of Microarray (SAM) and 
Support Vector Machine (SVM) for identiﬁcation of molecular classi-
ﬁers with respect to sample clustering results. Unsupervised hierarchi-
cal clustering revealed stable clustering of adenocarcinomas vs normal 
lungs, female-non-smokers vs other tumors, and tumors bearing EGFR 
mutation at exons 18 - 21 vs wildtype tumors. Supervised analysis 
identiﬁed discriminatory gene classiﬁers that predict lung adenocarci-
nomas (gene classiﬁers = 27, prediction sensitivity and speciﬁcity of 
100%), female non-smokers (gene classiﬁers = 22, prediction sensitiv-
ity of 65 - 85% and speciﬁcity of 84 - 94% with different independent 
validation sets) and EGFR mutation status (gene classiﬁers = 26, 
prediction sensitivity and speciﬁcity of 100%). Our data suggested that 
there is a group of Chinese female non-smokers with lung adenocarci-
nomas which displays gene expression proﬁles distinct from pulmonary 
adenocarcinomas from patients with other clinical characteristics. The 
identiﬁcation of gene classiﬁers could provide information for further 
study on lung adenocarcinomas, female non-smokers with lung cancer 
and lung tumors bearing EGFR mutations.
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Background: Peutz-Jeghers syndrome has been associated with muta-
tions in the LKB1 tumor suppressor gene. Somatic mutations of LKB1 
gene have been found in human cancers including non-small cell lung 
cancer (NSCLC) with adenocarcinoma histology. Reports with small 
number of cell lines and tumors have suggested the prevalence of 
LKB1 mutations in NSCLC to be ~30%. Relation of LKB1 mutations 
to the patient gender, age, smoking history, tumor stage and outcome, 
and their relationship to other commonly mutated genes in NSCLC is 
unknown. 
Methods: NSCLC tumor specimens (n = 167) with adenocarcinoma 
(n = 161) and adenosquamous carcinoma histologies (n = 6) were col-
lected from surgical resections and RNA was extracted using routine 
methods. Some of the specimens (n = 63) were collected in Korea, 
while rest of the specimens (n = 104) came from Caucasian patients 
from the US. Tumors were screened for LKB1 mutations using the 
SURVEYOR-WAVE method. In SURVEYOR-WAVE method, the 
whole coding region of LKB1 gene was PCR ampliﬁed in two overlap-
ping amplicons, PCR products were digested with SURVEYOR-en-
zyme which cleaves mismatches, and the specimens were analyzed 
with sensitive HPLC method for shorter digestion products. If digestion 
products were present, the specimen was sequenced using Sanger 
method to verify the mutation. Mutational analysis K-Ras, B-Raf, and 
EGFR hotpots were done either by SURVEYOR-WAVE method analo-
gously to LKB1 gene analysis or by direct sequencing with Sanger 
method. Statistical comparisons were done using Fisher’s exact test, p 
values < 0.05 were considered signiﬁcant 
Results: Mutations of the LKB1 gene were detected in twenty-two 
tumors (13%). Interestingly, twenty of the LKB1 mutations were 
detected in specimens collected in U.S. (prevalence 19%) while only 
two mutations (prevalence 3%) were detected in specimens from Asian 
origin (p = 0.004). The mutations were mainly deletions and insertions 
(82%) but some missense (9%), and nonsense (9%) mutations were 
also found. No correlation of LKB1 mutations to gender, age, or stage 
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was detected but there was tendency for LKB1 mutations occuring in 
smokers vs. non-smokers (p = 0.29). Furthermore, the outcome of stage 
I-II NSCLC patients treated with surgery alone did not differ based on 
LKB1 mutation status. K-Ras mutations were detected in thirty-two 
(19%) of tumor specimens with seven (21% of the K-Ras mutants) of 
these occurring concurrently with LKB1 mutations which, however, 
was statistically insigniﬁcant (p = 0.14). Three B-Raf mutations were 
detected but none of these occurred concurrently with LKB1 muta-
tions. Twenty-eight EGFR mutants (17%) were found with only one of 
them occurring concurrently with LKB1 mutation, which was missense 
outside the kinase domain of LKB1 (p = 0.13).
Conclusions: Mutations of LKB1 gene occur frequently in NSCLCs 
from Caucasian origin. There is tendency of coexistence in LKB1 and 
K-Ras mutations and exclusivity in LKB1 and EGFR mutations but 
these were statistically insigniﬁcant with our limited tumor material. 
Further studies are validated to clarify the outcome of LKB1 and K-Ras 
double mutation NSCLC patients and effect of LKB1 mutations to 
therapeutic responses in NSCLC. 
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Background: p53 intracellular poll is regulated by both MDM2 
induced degradation and p14ARF inhibition of MDM2-p53 complex 
formation. It was commonly accepted that p14ARF inhibits MDM2-
p53 complex by sequestering MDM2 in nucleoli. However in recent 
models, nucleophosmin (NMP) might sequester p14ARF in nucleoli 
preventing its inhibition of nucleoplasmic MDM2.
We studied whether MDM2, p14ARF and NPM expressions are modi-
ﬁed during early squamous carcinogenesis, the time course of appear-
ance of these abnormalities and relative intracellular localizations of 
these proteins.
Methods: 179 biopsies, including normal tissue, all type of bronchial 
preneoplastic lesions and early lung cancer were assessed for MDM2, 
p14ARF and NPM expressions using immunohistochemistry. 132 biop-
sies were evaluable for all three markers. 
Abnormal expression was deﬁned as follows: for MDM2, increased 
expression based on a score including intensity and number of positive 
cells (Eymin, 2002), for p14ARF, expression <10% or relocalization 
from the nucleoplasm to nucleoli in ≥10% of cells, for NMP, disappear-
ance from the nucleoplasm and concentration in nucleoli in ≥10% of 
cells.
Triple immunoﬂuorescent staining with antibodies directed against 
p14ARF, MDM2 and p53 (13 biopsies) and p14ARF, MDM2 and NPM 
(11) were performed, followed by laser scanning confocal microscopy.
Results: 
1) Expression
Aberrant expression was observed for all three proteins in lung preneo-
plastic lesions.
Protein
Type of  
abnormality
Histo-
pathological 
cut-oﬀ
Number of 
biopsies with 
aberrant 
expression
Number of 
biopsies with 
aberrant 
expression
p
   < cut-oﬀ = or > cut-oﬀ  
MDM2 overexpression mild dysplasia 22/94 (23%) 67/85 (79%) < 0.001
NPM relocalization  to nucleoli
moderate 
dysplasia 4/75 (5%) 16/61(26%) 0.034
p14ARF loss of  expression (1)
severe 
dysplasia 19/100 (19%) 23/44 (52%) 0.013
p14ARF relocalization  to nucleoli (2)
severe 
dysplasia 5/81 (6%) 8/21 (38%) < 0.001
p14ARF
aberrant 
expression  
(1) or (2)
severe 
dysplasia 24/100 (24%) 31/44 (70%) < 0.001
 
Aberrant p14ARF expression was statistically associated with MDM2 
overexpression: 75% and 85% of biopsies showing p14ARF loss or 
relocalization overexpressed MDM2.
2) Localization
Immunohistochemistry indicated that relocalizations of NPM and 
p14ARF to nucleoli were associated (p<0.001): 77% of biopsies ex-
pressing relocalized p14ARF showed relocalized NPM.
Immunoﬂuorescent staining indicated that MDM2 and p53 were local-
ized in the nucleoplasm of bronchial epithelial cells, excluding nucleoli.
Three patterns were observed for p14ARF: 1) not detected, 2) ex-
pressed either in nucleoli, 3) either in the nucleoplasm alone. 
Two patterns were observed for NPM: 1) present in nucleoli only, in 
which NPM colocalized with p14ARF but not with MDM2, 2) present 
both in nucleoli and in the nucleoplasm, in which NPM colocalized 
with nucleoplasmic p14ARF.
Conclusions: Our data suggest that MDM2, NPM and p14ARF could 
all play an active role early in lung squamous carcinogenesis: MDM2 
is already aberrantly expressed at the grade of mild dysplasia. p14ARF 
loss of expression or its relocalization from the nucleoplasm to nucleoli 
was associated with increased MDM2 expression. Both NMP and 
p14ARF, but not MDM2, are relocalized to nucleoli, supporting the 
hypothesis that relocalization of p14ARF in nucleoli might impair 
p14ARF-MDM2 complex formation.
